SHUKRA PHARMACEUTICALS Financial Statement Analysis
|
||
The Revenues of SHUKRA PHARMACEUTICALS have increased by 187.19% YoY .
The Earnings Per Share (EPS) of SHUKRA PHARMACEUTICALS has increased by 50.44 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
SHUKRA PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 524632]
Standalone | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
---|---|---|---|---|---|
Revenues | ₹59 Cr | ₹20 Cr | ₹11 Cr | ₹1,184,602 Cr | ₹5.66 Cr |
Expenses | ₹53 Cr | ₹18 Cr | ₹9.75 Cr | ₹1,030,567 Cr | ₹4.01 Cr |
Operating Profit (Excl OI) | ₹5.36 Cr | ₹2.89 Cr | ₹1.44 Cr | ₹154,035 Cr | ₹1.65 Cr |
Other Income | ₹1.20 Cr | ₹0.08 Cr | ₹0.36 Cr | ₹970 Cr | ₹0.04 Cr |
Interest | ₹0.28 Cr | ₹0.29 Cr | ₹0.03 Cr | ₹206 Cr | ₹0.00 Cr |
Depreciation | ₹1.84 Cr | ₹1.66 Cr | ₹1.47 Cr | ₹147,819 Cr | ₹0.96 Cr |
Profit Before Tax | ₹4.44 Cr | ₹1.02 Cr | ₹0.10 Cr | ₹17,084 Cr | ₹0.72 Cr |
Profit After Tax | ₹4.41 Cr | ₹0.75 Cr | ₹0.19 Cr | ₹3,560 Cr | ₹0.46 Cr |
Earnings Per Share (Rs) | ₹16.94 | ₹11.26 | ₹4.79 | ₹1.20 | ₹0.23 |
PAT Margin (%) | 24.86 | 7.49 | 3.66 | 1.68 | 0.26 |
ROE(%) | 44.70 | 21.16 | 4.70 | 1.21 | 0.23 |
ROCE(%) | 44.24 | 18.85 | 5.79 | 0.54 | 0.77 |
Total Debt/Equity(x) | 0.05 | 0.20 | 0.21 | 0.63 | 0.52 |
Key Financials |
||
Market Cap | : | ₹ 823.9 Cr |
Revenue (TTM) | : | ₹ 38.5 Cr |
Net Profit(TTM) | : | ₹ 14.4 Cr |
EPS (TTM) | : | ₹ 3.3 |
P/E (TTM) | : | 57.1 |
Industry Peers & Returns | 1W | 1M | 1Y |
SHUKRA PHARMACEUTICALS | 11.4% | 166.9% | 441.3% |
SUN PHARMACEUTICAL INDUSTRIES | -3.3% | -1.6% | 39.9% |
CIPLA | -1.4% | 1.1% | 17.1% |
DR REDDYS LABORATORIES | 0.3% | 9.4% | 19.1% |
ZYDUS LIFESCIENCES | 4.4% | 1.8% | 42% |
DIVIS LABORATORIES | -2.1% | -2.8% | 48.1% |
MANKIND PHARMA | -5.1% | 4.4% | 41.4% |
TORRENT PHARMACEUTICALS | -2.3% | -2.9% | 43.1% |
LUPIN | -7.1% | 1.9% | 62.9% |
SHUKRA PHARMACEUTICALS Revenues
[BOM: 524632]
Y-o-Y | 187.19 % |
5 Yr CAGR | 79.56 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹59 Cr | 187.19 | |
Mar2023 | ₹20 Cr | 82.98 | |
Mar2022 | ₹11 Cr | -100.00 | |
Mar2021 | ₹1,184,602 Cr | 20,929,263.25 | |
Mar2020 | ₹5.66 Cr | - |
SHUKRA PHARMACEUTICALS Operating Profit
[BOM: 524632]
Y-o-Y | 85.83 % |
5 Yr CAGR | 34.29 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹5.36 Cr | 85.83 | |
Mar2023 | ₹2.89 Cr | 99.86 | |
Mar2022 | ₹1.44 Cr | -100.00 | |
Mar2021 | ₹154,035 Cr | 9,341,035.23 | |
Mar2020 | ₹1.65 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -35.27 % |
5 Yr CAGR | -25.20 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 9.12% | -35.27 | |
Mar2023 | 14.09% | 9.22 | |
Mar2022 | 12.9% | -0.77 | |
Mar2021 | 13% | -55.37 | |
Mar2020 | 29.13% | - |
SHUKRA PHARMACEUTICALS Profit After Tax
[BOM: 524632]
Y-o-Y | 486.82 % |
5 Yr CAGR | 75.74 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹4.41 Cr | 486.82 | |
Mar2023 | ₹0.75 Cr | 299.47 | |
Mar2022 | ₹0.19 Cr | -99.99 | |
Mar2021 | ₹3,560 Cr | 770,549.35 | |
Mar2020 | ₹0.46 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | 231.91 % |
5 Yr CAGR | 212.70 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 24.86 % | 231.91 | |
Mar2023 | 7.49 % | 104.64 | |
Mar2022 | 3.66 % | 117.86 | |
Mar2021 | 1.68 % | 546.15 | |
Mar2020 | 0.26 % | - |
SHUKRA PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 524632]
Y-o-Y | 50.44 % |
5 Yr CAGR | 192.95 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹17 | 50.44 | |
Mar2023 | ₹11 | 135.07 | |
Mar2022 | ₹4.79 | 299.17 | |
Mar2021 | ₹1.20 | 421.74 | |
Mar2020 | ₹0.23 | - |
SHUKRA PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 524632]
Y-o-Y | 134.69 % |
5 Yr CAGR | 175.32 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 44.24% | 134.69 | |
Mar2023 | 18.85% | 225.56 | |
Mar2022 | 5.79% | 972.22 | |
Mar2021 | 0.54% | -29.87 | |
Mar2020 | 0.77% | - |
SHUKRA PHARMACEUTICALS Share Price vs Sensex
Current Share Price | : | ₹188.1 |
Current MarketCap | : | ₹ 823.9 Cr |
Updated EOD on | : | Jan 13,2025 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
SHUKRA PHARMACEUTICALS | 11.4% |
166.9% |
441.3% |
SENSEX | -2.1% |
-6.4% |
7% |
SHUKRA PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about SHUKRA PHARMACEUTICALS Financials
How the annual revenues of SHUKRA PHARMACEUTICALS have changed ?
The Revenues of SHUKRA PHARMACEUTICALS have increased by 187.19% YoY .
How the Earnings per Share (EPS) of SHUKRA PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of SHUKRA PHARMACEUTICALS has increased by 50.44 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs